Market Insight - Hepatitis C: in search of a breakthrough

Infection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the world's population, are chronically infected, and are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Estimates indicate that in the US, three to four million people are infected annually. The prevalence of HCV-related disease is increasing, but no vaccine is yet available.

Infection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the world's population, are chronically infected, and are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Estimates indicate that in the US, three to four million people are infected annually. The prevalence of HCV-related disease is increasing, but no vaccine is yet available.

Since HCV was identified as being the causative agent of Hepatitis C (non-A, non-B hepatitis), treatment has progressed rapidly, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

More from Therapeutic Category

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.